HC Wainwright Reiterates “Buy” Rating for Precision BioSciences (NASDAQ:DTIL)

HC Wainwright reiterated their buy rating on shares of Precision BioSciences (NASDAQ:DTIL) in a research note issued to investors on Friday,Benzinga reports. HC Wainwright currently has a $60.00 target price on the stock.

Separately, BMO Capital Markets raised shares of Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 target price on the stock in a report on Friday.

Precision BioSciences Price Performance

Shares of NASDAQ DTIL opened at $5.70 on Friday. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22. The company has a market cap of $43.72 million, a price-to-earnings ratio of 95.02 and a beta of 1.41. The stock’s 50-day moving average is $6.09 and its two-hundred day moving average is $8.25. Precision BioSciences has a 1-year low of $3.61 and a 1-year high of $19.43.

Institutional Trading of Precision BioSciences

An institutional investor recently raised its position in Precision BioSciences stock. Janus Henderson Group PLC lifted its holdings in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 10.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 702,069 shares of the company’s stock after acquiring an additional 68,943 shares during the period. Janus Henderson Group PLC owned 9.15% of Precision BioSciences worth $6,322,000 at the end of the most recent reporting period. 37.99% of the stock is owned by institutional investors and hedge funds.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.